Overview

MONITOR-CKD5 - Multi-level Evaluation of Anaemia Treatment, Outcomes, and Determinants in Chronic Kidney Disease Stage 5

Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
MONITOR-CKD5 is an observational, pharmaco-epidemiological study to evaluate the multi-level factors and outcomes associated with the treatment of renal anaemia with biosimilar epoetin alfa in Stage 5 CKD patients requiring haemodialysis.
Details
Lead Sponsor:
Sandoz
Collaborator:
Hexal AG
Treatments:
Epoetin Alfa